Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash from Operations: 2021-2025

Historic Cash from Operations for Roivant Sciences (ROIV) over the last 5 years, with Mar 2025 value amounting to -$839.5 million.

  • Roivant Sciences' Cash from Operations rose 30.41% to -$185.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 0.83%. This contributed to the annual value of -$839.5 million for FY2025, which is 9.69% down from last year.
  • As of FY2025, Roivant Sciences' Cash from Operations stood at -$839.5 million, which was down 9.69% from -$765.3 million recorded in FY2024.
  • Roivant Sciences' 5-year Cash from Operations high stood at -$552.1 million for FY2021, and its period low was -$843.4 million during FY2023.
  • Over the past 3 years, Roivant Sciences' median Cash from Operations value was -$839.5 million (recorded in 2025), while the average stood at -$816.0 million.
  • In the last 5 years, Roivant Sciences' Cash from Operations declined by 24.44% in 2023 and then rose by 9.26% in 2024.
  • Over the past 5 years, Roivant Sciences' Cash from Operations (Yearly) stood at -$552.1 million in 2021, then decreased by 22.75% to -$677.7 million in 2022, then declined by 24.44% to -$843.4 million in 2023, then rose by 9.26% to -$765.3 million in 2024, then declined by 9.69% to -$839.5 million in 2025.